Caspase 1 deficiency reduces inflammation-induced brain transcription

Date

Authors

Mastronardi, Claudio
Whelan, Fiona
Yildiz, Ozlem A.
Hannestad, Jonas
Elashoff, Robert M.
McCann, Samuel M.
Licinio, Julio
Wong, Ma-Li

Journal Title

Journal ISSN

Volume Title

Publisher

National Academy of Sciences (USA)

Abstract

The systemic inflammatory response syndrome (SIRS) is a life-threatening medical condition characterized by a severe and generalized inflammatory state that can lead to multiple organ failure and shock. The CNS regulates many features of SIRS such as fever, cardiovascular, and neuroendocrine responses. Central and systemic manifestations of SIRS can be induced by LPS or IL-1β administration. The crucial role of IL-1β in inflammation has been further highlighted by studies of mice lacking caspase 1 (casp1, also known as IL-1β convertase), a protease that cleaves pro-IL-1β into mature IL-1β. Indeed, casp1 knockout (casp1-/-) mice survive lethal doses of LPS. The key role of IL-1β in sickness behavior and its de novo expression in the CNS during inflammation led us to test the hypothesis that IL-1β plays a major role modulating the brain transcriptome during SIRS. We show a gene-environment effect caused by LPS administration in casp1 -/- mice. During SIRS, the expression of several genes, such as chemokines, GTPases, the metalloprotease ADAMTS1, IL-1RA, the inducible nitric oxide synthase, and cyclooxygenase-2, was differentially increased in casp1 -/- mice. Our findings may contribute to the understanding of the molecular changes that take place within the CNS during sepsis and SIRS and the development of new therapies for these serious conditions. Our results indicate that those genes may also play a role in several neuropsychiatric conditions in which inflammation has been implicated and indicate that casp1 might be a potential therapeutic target for such disorders.

Description

Citation

Source

PNAS - Proceedings of the National Academy of Sciences of the United States of America

Book Title

Entity type

Access Statement

License Rights

Restricted until

2037-12-31